AGC Biologics products

AGC Biologics has extensive experience developing mammalian and microbial production cell lines. This experience combined with our advanced analytical capabilities enable us to identify and select clones that meet your product’s specific parameters and characteristics. After selecting the most appropriate clones, we optimize production conditions to develop a high productivity cell line, tailored to your specific product quality targets and target production level, designed for robust, scalable manufacturing.

AGC Biologics has provided solutions to customers on five continents and has developed more than 60 mammalian cell lines and processes from pre-clinical through commercial production. We have skillfully developed upstream processes for numerous expression systems, including our proprietary CHEF1® Expression Platform, which has been used extensively to create clinical and commercial production cell lines. Our extensive experience enables us to identify and select cell types that meet specific parameters and characteristics and to optimize our customers’ product attributes. Our CHEF1 Platform enables rapid and seamless process transfer of your product to cGMP manufacturing.

Downstream bioprocessing steps have long held challenges for drug manufacturers, particularly the chromatography step for purification of monoclonal antibodies (mAbs). The complexity of traditional chromatography options as well as the high cost of the Protein A resin required have driven the search for a more flexible, cost-effective and convenient alternative.